CRISPR Gene Editing Market to Reach US$ 12.78 Billion by 2033, Driven by Breakthrough Approvals, Advanced Editing Tools, and Expanding Therapeutic Pipelines | DataM Intelligence

According to DataM Intelligence, the global CRISPR gene editing market reached US$ 4.67 billion in 2024 (up from US$ 4.21 billion in 2023) and is expected to reach US$ 12.78 billion by 2033, growing at a CAGR of 11.9% during 2025-2033. Growth is fueled by accelerating clinical translations, regulatory milestones for CRISPR-based therapies, rising investments in gene editing platforms, and expanding applications in therapeutics, agriculture, and research.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/crispr-gene-editing-market?jd

North America Key Industry Developments
✅ December 2025: Vertex Pharmaceuticals and CRISPR Therapeutics announced expanded access programs and additional regulatory submissions for CASGEVY (exagamglogene autotemcel) following successful launches in sickle cell disease and beta-thalassemia.
✅ December 2025: Editas Medicine reported positive interim data from ongoing Phase 1/2 trials of EDIT-301 for severe sickle cell disease, with further dose escalation and enrollment progress.
✅ January 2026: Thermo Fisher Scientific Inc. launched new high-efficiency CRISPR/Cas9 kits and reagents optimized for in-vivo delivery, strengthening its dominance in the tools segment.

Asia-Pacific Key Industry Developments
✅ December 2025: Chinese biotech firms, including those in partnership with global players, advanced CRISPR-based agricultural trials with new approvals for gene-edited crops in select provinces.
✅ December 2025: GenScript expanded its CRISPR service offerings in Asia with new facilities supporting prime and base editing for therapeutic development.
✅ January 2026: Increased government funding and collaborations in South Korea and Japan accelerated CRISPR research in rare diseases and oncology, boosting regional adoption.

Key Mergers and Acquisitions
✅ Strategic Alliance: Major tool providers like Merck and Agilent Technologies strengthened partnerships for integrated CRISPR workflows and custom reagent development.
✅ Platform Expansion: Leading players pursued licensing deals and collaborations for next-generation editing technologies such as prime and epigenetic editing.

Purchase this report before year end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=crispr-gene-editing-market
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis
- By Product: Kits and Reagents dominate with 60.5% market share in 2024; Instruments segment supports growing lab automation.
- By Gene Editing Modality: Ex-Vivo Editing leads due to approved therapies; In-Vivo Editing gains momentum with delivery advancements.
- By Technology: CRISPR/Cas9 holds 35.3% share in 2024, followed by CRISPR/Cas12, CRISPR/Cas13, Base Editing, Prime Editing, Epigenetic Editing, and Others.
- By End User: Academic and Research Institutes and Biotechnology and Pharmaceutical Companies lead demand, with growth in Agricultural and Livestock Industry, Hospitals and Clinics, Contract Research Organizations (CROs), and Others.

Regional Insights
North America dominates the global CRISPR gene editing market with a 48.5% revenue share in 2024, driven by strong biotech ecosystem, FDA approvals, venture funding, and leadership in therapeutic development. Asia-Pacific is the fastest-growing region, supported by rising R&D investments, agricultural applications, and expanding biotech infrastructure.

Growth Drivers
- Increasing number of CRISPR-based therapies entering clinical stages and gaining regulatory approvals
- Advancements in precision editing tools like prime, base, and epigenetic editing
- Growing demand for CRISPR kits, reagents, and instruments in research and therapeutic development
- Expanding applications in rare diseases, oncology, agriculture, and personalized medicine
- Strategic collaborations, funding, and regional initiatives accelerating global adoption

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/crispr-gene-editing-market?jd

Key Players
The market includes leading companies such as Thermo Fisher Scientific Inc., New England Biolabs, Lonza Bioscience, Merck, Integrated DNA Technologies, Inc., Synthego, GenScript, Takara Bio Inc., QIAGEN, and Agilent Technologies, Inc., among others.

Key Highlights (Top 5 Key Players)
- Thermo Fisher Scientific Inc. - Leading in CRISPR kits and reagents with new high-efficiency launches and broad market penetration.
- Merck - Advancing integrated CRISPR solutions and custom editing services for therapeutic and research applications.
- Synthego - Expanding high-precision CRISPR tools and automation platforms for accelerated genome editing.
- GenScript - Strengthening global CRISPR service offerings, including advanced modalities like prime editing.
- Agilent Technologies, Inc. - Driving innovation in CRISPR reagents and next-generation editing technologies.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.